台灣臨床試驗主持人資料庫|TPIDB

問卷

Log In

繁中 EN

TPIDB

TPIDB Outstanding PI

TPIDB > Study Site > 收納受試者人數排名

Search Result

List

55Cases

2017-06-01 - 2019-12-31

Phase II/III

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Condition/Disease

Advanced or Metastatic Biliary Tract Cancer
Test Drug

Varlitinib

Participate Sites
7Sites

Terminated5Sites

白禮源

China Medical University Hospital-Taipei

未分科

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-07-01 - 2020-01-31

Others

A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH)

Condition/Disease

non-alcoholic steatohepatitis (NASH)
Test Drug

LJN452 (tropifexor)

Participate Sites
8Sites

Terminated6Sites

黃志富

Kaohsiung Municipal Gangshan Hospital

未分科

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Condition/Disease

Non-small cell lung cancer
Test Drug

HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華

Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-11-16 - 2022-01-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Condition/Disease

Diabetic kidney disease
Test Drug

BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯

Taipei Medical University Hospital

Division of Nephrology

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2015-11-26 - 2022-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Condition/Disease

Diabetic kidney disease
Test Drug

BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯

Taipei Medical University Hospital

Division of Nephrology

唐德成

Taipei Veterans General Hospital

Division of Nephrology

1 Previous page 2 3 4 5 6